Noninvasive Identification of Viable Cell Populations in Docetaxel-Treated Breast Tumors Using Ferritin-Based Magnetic Resonance Imaging

YoonSeok Choi1,2, Hoe Suk Kim1,3, Kyoung-Won Cho1, Kyung-Min Lee4, Yoon Jung Yi1, Sung-Jong Eun6, Hyun Jin Kim1, Jisu Woo1,3, Seung Hong Choi1, Taeg-Keun Whangbo6, ChulSoo Choi5, Dong-Young Noh4, Woo Kyung Moon1,2*

1 Department of Radiology, Seoul National University Hospital, Seoul, Korea, 2 Department of Biomedical Science, College of Medicine, Seoul National University, Seoul, Korea, 3 The Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul, Korea, 4 Department of Surgery, Seoul National University Hospital, Seoul, Korea, 5 Institute of LeeGilYeo Cancer and Diabetes Center, Gachon University of Medical Science, Incheon, Korea, 6 Department of Computer Science, Gachon University, Seongnam, Korea

Abstract

Background: Cancer stem cells (CSCs) are highly tumorigenic and are responsible for tumor progression and chemoresistance. Noninvasive imaging methods for the visualization of CSC populations within tumors in vivo will have a considerable impact on the development of new CSC-targeting therapeutics.

Methodology/Principal Findings: In this study, human breast cancer stem cells (BCSCs) transduced with dual reporter genes (human ferritin heavy chain [FTH] and enhanced green fluorescence protein [EGFP]) were transplanted into NOD/SCID mice to allow noninvasive tracking of BCSC-derived populations. No changes in the properties of the BCSCs were observed due to ferritin overexpression. Magnetic resonance imaging (MRI) revealed significantly different signal intensities (R2* values) between BCSCs and FTH-BCSCs in vitro and in vivo. In addition, distinct populations of pixels with high R2* values were detected in docetaxel-treated FTH-BCSC tumors compared with control tumors, even before the tumor sizes changed. Histological analysis revealed that areas showing high R2* values in docetaxel-treated FTH-BCSC tumors by MRI contained EGFP+/FTH+ viable cell populations with high percentages of CD44+/CD24− cells.

Conclusions/Significance: These findings suggest that ferritin-based MRI, which provides high spatial resolution and tissue contrast, can be used as a reliable method to identify viable cell populations derived from BCSCs after chemotherapy and may serve as a new tool to monitor the efficacy of CSC-targeting therapies in vivo.

Citation: Choi Y, Kim HS, Cho K-W, Lee K-M, Yi YJ, et al. (2013) Noninvasive Identification of Viable Cell Populations in Docetaxel-Treated Breast Tumors Using Ferritin-Based Magnetic Resonance Imaging. PLoS ONE 8(1): e52931. doi:10.1371/journal.pone.0052931

Introduction

Since the first identification of breast cancer stem cells (BCSCs) from human tumor samples using CD44+/CD24− markers by Al-Hajj et al., the role of BCSCs in tumor progression and therapeutic resistance has been actively investigated to develop better anti-cancer treatment strategies [1,2]. In breast cancer patients, administration of chemotherapy or radiation therapy increases the fraction of CD44+/CD24− tumor cells and augments mammosphere formation in vitro and tumorigenicity in xenotransplantation models [3,4]. The presence of BCSC markers or gene expression signatures correlates with poor prognosis in clinical tumor samples [5,6]. The therapeutic resistance of BCSCs is associated with alterations in self-renewal and cell fate signaling pathways, including Notch, Wnt, Hedgehog, and HER-2 [2]. New therapeutic regimens using single agents or a combination of various drugs that target BCSCs are now under preclinical or clinical trials. Monitoring the efficacy of cancer stem cell (CSC) therapeutics in vivo, however, is challenging because the conventional method of measuring tumor size is inadequate as an endpoint [7]. In vivo identification of BCSCs using cellular imaging techniques will be extremely useful for this purpose because the efficacy of treatment depends more on the fraction of viable cancer cells in the tumor [8,9].

In vivo imaging methods, including intravital microscopy, fluorescent imaging, luciferase imaging, positron emission tomography (PET), and magnetic resonance imaging (MRI), have been used to track cancer cells and monitor treatment response [10–15]. However, there have only been a few reports of in vivo imaging of CSCs in different types of tumors [16,17]. Snyder et al. analyzed CSCs using quantum dot-conjugated antibodies against CD44v6 and CD24 in tumors and suggested
the possibility of applying this approach to BCSC imaging [12]. Vlashi et al. demonstrated reduced 26S proteasome activity in CSCs originating from glioma cells and monitored these CSCs in vivo using a fluorescent protein (ZsGreen) fused to ornithine decarboxylase, which is a target of the 26S proteasome [13]. Liu et al. longitudinally monitored CSCs derived from breast cancer patients in an orthotopic xenograft mouse model using ubiquitin promoter-driven luciferase and showed the role of BCSCs in metastasis with imaging techniques [14]. Recently, Yoshii et al. showed that in a mouse colon carcinoma model, Cu-64-ATSM, a PET imaging agent, localizes preferentially in tumor regions with a high density of CD133+ cells with CSC characteristics [15]. However, in vivo imaging of BCSCs using MRI or PET has not been reported to date. MRI can provide tomographic or volumetric imaging of internal organs at high anatomical resolutions and soft tissue contrast without using ionizing radiation, which is not possible with other imaging modalities. Clinically, MRI is routinely used to identify and localize tumors before surgery and to monitor the response to treatment in breast cancer [10].

There are two approaches to track and image cells of interest in vivo with MRI. The first method uses a contrast agent as a labeling or targeting agent. To date, superparamagnetic iron oxide (SPIO) nanoparticles, due to their high relaxivity, have been the most widely used contrast agents for tracking and imaging diverse cells [19,20]. With surface modification of SPIO nanoparticles, cells of interest can be targeted by an antibody, peptide, or nucleotide conjugation [21]. The presence of SPIO nanoparticles in the magnetic field leads to low signal intensities in T2 or T2* sensitive images. However, this method does not enable the long-term imaging of the cells of interest because the contrast agents become diluted as the cells divide, and the SPIO nanoparticle signals can accumulate in sites within tumors, where the cells are not viable [9]. The use of the MRI reporter gene ferritin can overcome these limitations [22-26]. The overexpression of ferritin enables cells to uptake more iron, and this reporter produces low signal intensities in MRI. As MRI reporters are stably expressed, even during cell division, they can be used for studying dynamic processes, e.g., the migration and invasion of cells of interest over an extended period of time and can also be useful for providing temporal and spatial information for anti-cancer treatment effects on a specific cell population. The number of cancer cells or level of tumor burden in deep tissues can be quantified by calculating R2* (= 1/T2*) values from T2* mapping of MRI images [27,28].

In the present study, BCSCs isolated from human breast cancer specimens were transduced with MRI (human ferritin heavy chain, FTH) and fluorescence (enhanced green fluorescence protein, EGFP) dual reporter genes and transplanted into nude mice diabetic/severe combined immunodeficient (NOD/SCID) mice to noninvasively track BCSC-derived populations during tumor growth and monitor tumor responses after chemotherapy. An MRI evaluation of ferritin-overexpressing BCSCs (FTH-BCSCs) was performed, and the tumor response to chemotherapy was determined by quantification of the R2* values for entire tumors. In addition, viable cells were identified and localized by volumetric MRI, and BCSC characteristics were investigated by histological analysis.

**Methods**

**Ethics Statement**

All of the procedures were performed following approval by the Institutional Review Board (IRB) at Seoul National University Hospital. IRB approval number is H-0502-142-007. The individual in this manuscript has given written informed consent (as outlined in PLOS consent form) with the Declaration of Helsinki to publish these case details.

In animal study, 6-week-old NOD/SCID female mice were used. The animal study was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC; No.11-0105) of the Seoul National University Hospital, and the procedures for all animal experiments were performed according to IACUC guidelines.

**Isolation of Primary BCSCs and Establishment of FTH-BCSCs**

The human breast cancer tissues were obtained in operating room within 30 minutes after excision from routine surgical procedures for breast cancer patients. After excision from the surgical procedures, tissues (ER-, PR-, HER2-) were minced into 1 mm3 sized pieces and digested with collagenases at 37 °C for four hour. After rinsing with the proper amount of medium used for mammosphere culture, CD44+/CD24- cells were obtained with fluorescence-activated cell sorter (FACS-Aria, BD Biosciences) and maintained using an anchorage-independent culture method [29]. The BCSCs were incubated with DMEM mixed 3:1 with Ham’s F12 medium (Invitrogen) supplemented with basic fibroblast growth factor (10 ng/ml; Millipore), epidermal growth factor (20 ng/ml; Invitrogen), leukemia inhibitory factor (10 ng/ml; Millipore), B27 supplement (Invitrogen) and antibiotic-antimycotic solution (Invitrogen) for mammosphere culture.

To establish the FTH-BCSCs, a lentivirus expressing nyc-tagged FTH (myc-FTH) and EGFP driven by the cytomegalovirus (CMV) and phosphoglycerate kinase (PGK) promoters, respectively, was introduced into cells by incubating the cells with 107–108 transduction units/ml for 6–10 hours in the presence of 8 µg/ml polybrene. After three days of transduction, cells expressing EGFP were sorted using a FACS-Aria, expanded and used in all experiments.

**Analysis of Surface Markers on FTH-BCSCs**

To analyze cell surface markers, 5×103 BCSCs and FTH-BCSCs were dissociated from mammospheres and washed two times with phosphate buffered saline (PBS) containing 1% BSA. The cells were then incubated with anti-huCD44-phycocerythrin (PE), anti-huCD24-PE, anti-huCD90-APC, anti-huCD105-PE or anti-huCD34-PE antibodies (BD Biosciences) for one hour at 37 °C. Cell-associated fluorescence was measured using a FACScan Calibur flow cytometer (BD Biosciences). The data were analyzed using CellQuest software (BD Biosciences).

**Western Blot Analysis**

Cells were lysed in RIPA buffer with 1 mM phenylmethylsulfonyl fluoride and a protease inhibitor cocktail (Sigma-Aldrich Chemical Co.). The protein lysates were resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) for four hours at room temperature and were transferred to nitrocellulose membranes for two hours at 4°C. After blocking, the membranes were incubated with anti-FTH (Santa Cruz Biotechnology) and anti-EGFP (Santa Cruz Biotechnology) antibodies overnight at 4°C followed by incubation with HRP-conjugated antibodies (Santa Cruz Biotechnology) at room temperature for 30 minutes.
Blots were visualized using enhanced chemiluminescence reagents (Amersham Biosciences).

**Immunocytochemistry of Mammospheres**

Mammospheres were fixed in 4% paraformaldehyde in PBS. For the detection of myc-FTH expression, fixed mammospheres were incubated with anti-myc antibody (Santa Cruz Biotechnology) overnight at 4°C followed by incubation with the Alexa Fluor 594-conjugated anti-mouse IgG antibody (Invitrogen) at room temperature for one hour. Hoechst 33342 (Invitrogen) was used to visualize cell nuclei. Images were scanned and analyzed with a confocal laser microscope (LSM 5 META, Carl Zeiss).

**Measurement of Iron Loading**

BCSCs or FTH-BCSCs (2×10³) were placed in 12-well Petri dishes, and 0 to 50 µM ferric ammonium citrate (FAC; Sigma-Aldrich Chemical Co.) was added to the culture medium for 4 days. Harvested cells were counted and subsequently lysed with 6 N HCl to extract total iron. The amount of total iron was measured using a colorimetric method. Fluorescence Imaging

**Fluorescence Imaging**

At three weeks post-injection, the fluorescence imaging of BCSC and FTH-BCSC tumors from a living mouse was assessed using a Maestro imaging system (CRi Inc.) with excitation and emission set at 445–490 nm and 515 nm, respectively. The filter was adjusted while the camera captured images, and the signals from the tumors were merged with a GFP-filtered image.

**Ex vivo** fluorescence imaging of BCSC and FTH-BCSC tumors excised from mice was performed by GFP fluorescence analysis (excitation: 470 nm, emission: 535 nm) using a Kodak Image Station 4000MM (Carestream Molecular Imaging).

**Docetaxel Treatment and Cytotoxicity Assays**

To investigate the *in vivo* cytotoxicity of docetaxel on BCSCs and FTH-BCSCs, JC-1 staining and 3,2,5-diphenyltetrazolium bromide (MTT) assays were performed following treatment with docetaxel (1–10 nM, Sigma-Aldrich Chemical Co.) for 24 hours. To evaluate the changes in the mitochondrial membrane potential of both cell populations treated with docetaxel, the mitochondrial vital dye JC-1 (10 µg/mL, Invitrogen) was used. JC-1 aggregates with intense red fluorescence are known to accumulate in the intact mitochondria of healthy cells. When the mitochondrial membrane potential collapses in non-viable cells, JC-1 monomers fluoresce green. The percentage of cells with intact mitochondrial membranes was calculated by dividing the number of red fluorescence-positive cells by the total cell number.

**In vivo Docetaxel Treatment**

The mice with BCSC (n = 18) and FTH-BCSC (n = 18) tumors were divided into docetaxel-treated (n = 19) and untreated control groups (n = 17). Docetaxel was treated when the tumor volumes had 70 mm³, usually 16 to 18 days after tumor cell implantation. In the docetaxel-treated groups, docetaxel (15 mg/kg) was injected into the tail vein of mice three times at intervals of 72 hours to evaluate the therapeutic effect of docetaxel on BCSC and FTH-BCSC tumors. The BCSC and FTH-BCSC tumors in the docetaxel-treated group are represented as BCSC Doc tumors (n = 10) and FTH-BCSC Doc tumors (n = 9), respectively. In the control group (BCSC tumors [n = 8]; FTH-BCSC tumors [n = 9]), saline was intravenously injected three times at the same intervals as those used in the docetaxel-treated groups.

**MRI Examination**

All MRI studies were performed on a 9.4-T Bruker Biospec scanner (Bruker Biospin). A transmit-only volume coil and a four-channel surface coil (Bruker Biospin) were used for excitation and signal reception, respectively. For *in vivo* MRI, phantoms containing 2×10⁷ BCSCs and FTH-BCSCs, which were treated with or without 25 µM FAC for 4 days, were prepared. A multi-slice, multi-echo gradient echo sequence was used for *in vivo* T₂* mapping. The parameters were as follows: matrix size = 256×256, repetition time (TR) = 5000 ms, slice thickness = 1 mm (no gap), flip angle = 90°, field of view (FOV) = 25×25 mm², TE = 3.1–43.1 ms with a step size of 10 ms (five-point T₂* mapping), 13 slices and 4 signal averages.

*In vivo* MRI of mice bearing xenograft tumors, 1×10⁶ BCSCs or FTH-BCSCs were injected into the mammary fat pads of NOD/SCID mice. For whole-animal MRI, mice were anesthetized with isofluorane (1% in 100% oxygen). To stabilize the body temperature of the mice during MRI experiments, an animal warming system (Bruker Biospin) was used. Pre-treatment images were obtained three weeks after injection, and longitudinal follow-up images were obtained at 5 and 14 days after docetaxel treatment. *In vivo* data were acquired for fat saturation. The parameters were as follows: matrix size = 256×256, TR = 5000 ms, slice thickness = 1 mm (no gap), flip angle = 90°, FOV = 37×37 mm², TE = 3.1–34.4 ms with a step size of 4.4 ms (eight-point T₂* mapping), 17 slices and 1 signal average.
were considered to be statistically significant. Differences in the R2* distribution better, we defined the mean plus the mean R2* values among the animal groups were performed including all pixels in the ROIs across all slices. Comparisons of values of each group of tumors were calculated for the comparison images, assuming single exponential decay. After performing the estimated by pixel-by-pixel analyses across the multi-point MRI.

Characteristics

The Transduction of FTH and EGFP does not Alter BCSC Characteristics

BCSCs from a breast cancer patient with a CD44+/CD24− phenotype were isolated and maintained using mammosphere culture media (Figure 1A). To establish ferritin-overexpressing BCSCs, genes for myc-FTH and EGFP were transduced into cells with a lentiviral vector, and fluorescence-activated cell sorting (FACS) was used to collect the cells that expressed both myc-FTH and EGFP. The levels of BCSC markers (CD44+/CD24−) did not change in the FTH-BCSCs (Figure 1B). Immunofluorescence staining and western blot analysis revealed the expression of myc-FTH and EGFP in FTH-BCSCs (Figure 1C and D). Iron-loading abilities were investigated with the addition of up to 50 μM of FAC to both the FTH-BCSCs and BCSCs. The cellular iron levels of both groups increased in a dose-dependent manner, but the FTH-BCSCs had significantly higher iron levels compared with the BCSCs (Figure 1E; P<0.05 in 25 and 50 μM of FAC).

Next, we sought to determine whether the FTH-BCSCs retained their BCSC properties compared to control BCSCs. The mammosphere-forming abilities and surface marker expression of the BCSCs and FTH-BCSCs were compared. Four days after single-cell dissociation, BCSCs and FTH-BCSCs generated mammospheres, and no substantial differences were observed in the average numbers of mammospheres (Figure S1A). The human mammary stem cell marker CD49f was highly expressed in both BCSCs and FTH-BCSCs [30]. High levels of CD90 (mesenchymal lineage marker) and low levels of CD34 (hematopoietic stem cell marker) were observed, and the levels of all of these surface markers did not differ between the FTH-BCSCs and BCSCs (Figure S1B and C).

Next, we performed a tumor forming ability assay with serially diluted numbers of BCSCs and FTH-BCSCs to investigate whether ferritin overexpression affects tumorigenesis in vivo (Figure S2A). Various numbers of BCSCs or FTH-BCSCs were xenografted into the mammary fat pads of mice, and the incidence of the BCSC and FTH-BCSC tumors following engraftment with 2×10⁶ cells was approximately 25% with transplantation of more than 1×10⁷ BCSCs or FTH-BCSCs, resulting in 100% tumor formation (Table 1). The sizes of the BCSC and FTH-BCSC tumors were similar. ex vivo fluorescence imaging showed the stable expression of EGFP in the FTH-BCSC tumors (Figure S2B). These results demonstrated that the FTH-BCSCs retained the characteristics of BCSCs, despite the overexpression of FTH and EGFP.

We also investigated the effects of iron overload on the growth and viability of the BCSCs and FTH-BCSCs. The growth rates of the BCSCs and FTH-BCSCs were not affected by treatment with FAC (Figure S3A). Cytotoxicity was not observed in either group following treatment with 25 μM FAC (Figure S3B), which is regarded as the physiological iron concentration in mouse serum (250–350 μg/dl) [31]. Taken together, these findings demonstrate that the FTH-BCSCs retained the biological properties of the parent BCSCs and possessed an enhanced ability for iron storage, suggesting the feasibility of FTH-BCSC MRI in vivo and in vitro.

FTH-BCSCs Exhibit a Significant Increase in R2* Values in MRI Compared to BCSCs

To analyze the R2* values of the BCSCs and FTH-BCSCs, cells were incubated with or without 25 μM FAC, and MRI images of cell phantoms were obtained (Figure 2A). The mean R2* values of the FTH-BCSCs (97.85±0.51 s⁻¹) treated with 25 μM FAC were significantly higher than those of the BCSCs (90.72±0.21 s⁻¹). However, the mean R2* values of the FTH-BCSCs and BCSCs in the absence of FAC were not different (Figure 2B).

Next, we investigated the effect of ferritin overexpression in a xenograft tumor model. Lower signal intensities were observed in the MRI images of FTH-BCSC tumors compared with BCSC tumors due to ferritin overexpression (Figure 2C, left). A color-coded map of BCSC and FTH-BCSC tumors revealed variable R2* values (Figure 2C, right). Although both the BCSC and FTH-BCSC tumors exhibited differences in the R2* values within the tumors, the FTH-BCSC tumors exhibited higher mean R2* values compared with the BCSC tumors, and the FTH-BCSC tumors exhibited shifted R2* distributions toward higher R2* values.
Figure 1. Establishment of breast cancer stem cells (FTH-BCSCs) that overexpress the myc-tagged heavy chain subunit of ferritin (myc-FTH) and EGFP. (A) Flow cytometric analysis of the surface markers, CD44 and CD24 in BCSCs isolated from human breast cancer specimens. (B) Flow cytometric analysis of the surface markers, CD44 and CD24 in FTH-BCSCs expressing myc-FTH and EGFP. (C) Immunocytochemistry of BCSCs and FTH-BCSCs (bar, 50 μm). (D) Western blot analysis for myc-FTH and EGFP in BCSCs and FTH-BCSCs. (E) Measurement of cellular iron in BCSCs and FTH-BCSCs treated with increasing concentrations of ferric ammonium citrate (FAC). The results were obtained from 4 independent experiments and are presented as means ± SD. *P<0.05.

doi:10.1371/journal.pone.0052931.g001
MRI Reveals Distinct Populations of Pixels with High R₂* Values within Docetaxel-treated FTH-BCSC Tumors

Next, we evaluated the potential use of FTH-based MRI for monitoring the efficacy of an anti-cancer drug in xenografted tumors. We found that the growth of docetaxel-treated BCSC Doc and FTH-BCSC Doc tumors was attenuated compared to BCSC and FTH-BCSC tumors. Additionally, overexpression of FTH did not affect tumor growth (Figure S4).

We subsequently performed slice-by-slice MRI analysis of tumors from each group and observed different distributions of tumor R₂* values in volumetric images with longitudinal follow-up scans (Figure 3A and Figure S5). Before docetaxel treatment, the R₂* value distribution between BCSC and BCSC Doc tumors and that between FTH-BCSC and FTH-BCSC Doc tumors were similar (Figure 3B and Table 2). At day 5 of docetaxel treatment, the mean R₂* values of the BCSC Doc and FTH-BCSC Doc tumors were significantly decreased compared with the BCSC and FTH-BCSC tumors (P<0.05; Figure 3C and Table 2). At day 14 of docetaxel treatment, the BCSC Doc and FTH-BCSC Doc tumors exhibited lower mean R₂* values compared with the BCSC and FTH-BCSC tumors (P<0.01; Figure 3D and Table 2). Notably, histogram analysis revealed that only the FTH-BCSC Doc tumors at day 14 of docetaxel treatment had distinct populations of pixels with high R₂* values and a distribution of

Table 1. Evaluation of the incidence of tumors in NOD/SCID mice implanted with different numbers of BCSCs and FTH-BCSCs.

| Cell type   | Cell numbers | Tumor incidence |
|-------------|--------------|-----------------|
| BCSC        | 1×10⁶        | 3/3             |
|             | 1×10⁷        | 6/6             |
|             | 1×10⁸        | 4/4             |
|             | 1×10⁹        | 4/4             |
|             | 2×10⁷        | 1/4             |
| FTH-BCSC    | 1×10⁶        | 3/3             |
|             | 1×10⁷        | 6/6             |
|             | 1×10⁸        | 4/4             |
|             | 1×10⁹        | 4/4             |
|             | 2×10⁷        | 1/4             |

doi:10.1371/journal.pone.0052931.t001

(Figure 2D; mean R₂* values of BCSC tumors vs. FTH-BCSC tumors; 87.2±2.7 s⁻¹ vs. 105.4±3.8 s⁻¹; P<0.01).

Figure 2. MRI images of phantom cells and xenograft tumors. (A) In vitro MRI images (left) and color-coded maps (right) of agarose phantoms of BCSCs and FTH-BCSCs treated with or without 25 μM FAC. (B) R₂* values measured from MRI images of BCSC and FTH-BCSC phantoms. *P<0.05. (C) In vivo MRI images (left) and color-coded maps (right) of BCSC and FTH-BCSC xenograft tumors in the mammary fat pads of NOD/SCID mice. (D) The distributions of the R₂* values obtained for the BCSC and FTH-BCSC tumors at 3 weeks post-transplantation.

doi:10.1371/journal.pone.0052931.g002
**Table 2.** Mean R2* values of control (BCSC and FTH-BCSC) and docetaxel-treated (BCSC Doc and FTH-BCSC Doc) xenograft tumors.

|          | Mean R2* value ± SD (sec⁻¹) | P value |
|----------|-----------------------------|---------|
|          |                             |         |
| BCSC     | 83.30 ± 6.30                | 0.12    |
| FTH-BCSC | 81.78 ± 6.58                | 0.03*   |
| Day 0    | 79.47 ± 8.30                |         |
| Day 5    | 65.11 ± 5.49                |         |
| Day 14   | 43.32 ± 7.89                | 0.001** |
| FTH-BCSC | 96.94 ± 8.45                | 0.18    |
| FTH-BCSC | 94.99 ± 8.20                | 0.02*   |
| FTH-BCSC | 55.26 ± 9.16                | 0.001** |

NOTE: Values in bold are statistically significant (*, P<0.05 and **, P<0.01).

doi:10.1371/journal.pone.0052931.t002

R2* values that was skewed compared with the other groups (Figure 3D). In the FTH-BCSC Doc tumors, pixels that represented a distinct population and were measured over the threshold value (mean ±3SD; Table S1) occupied approximately 50% of the total pixels, while the percentages of all the other groups were less than 50% (P<0.05, Figure 3E).

**Histological Analysis Reveals that the Cell Populations with High R2* Values are Localized in Viable Areas of the FTH-BCSC Tumors**

Next, we performed histological analysis to investigate whether ferritin-based MRI images reflects the tissue state after docetaxel treatment. MRI showed that the R2* value pixels were similarly distributed between the periphery and center of both BCSC and FTH-BCSC tumors and H&E staining revealed that most of the cells in the periphery and center of the BCSC and FTH-BCSC tumors were viable (Figure 4A and C). In contrast, MRI showed that the R2* value pixels were differently distributed between the periphery and center of BCSC Doc and FTH-BCSC Doc tumors and H&E staining revealed that the center of BCSC Doc tumors with low R2* values had both viable and nonviable cell populations (Figure 4B, right), whereas the center of the FTH-BCSC Doc tumors with mixed high and low R2* values matched those of the viable and nonviable cells within the tumors, respectively (Figure 4D, right). In addition, the periphery of BCSC Doc and FTH-BCSC Doc tumors with high R2* values had viable cells whereas viable cells were also found in the periphery of the BCSC Doc tumors with low R2* values (Figure 4B, left). The presence of viable cells in the FTH-BCSC periphery and FTH-BCSC Doc tumors was confirmed with EGFP fluorescence (Figure S6). Additionally, we investigated the co-expression of myc-FTH and EGFP in the FTH-BCSC and FTH-BCSC Doc tumors and confirmed that the EGFP-positive cells had the myc-FTH expression (Figure 4E).

To clarify whether ferritin overexpression alters the therapeutic response to docetaxel, cell viability was evaluated by mitochondrial membrane potential analysis and MTT assay after treatment with docetaxel. Docetaxel induced a depolarization of the mitochondrial membrane potentials and reduced the intact mitochondrial membrane in both BCSCs and FTH-BCSCs (Figure S7A). A decrease in cell viability in the FTH-BCSCs and BCSCs were observed in a docetaxel dose-dependent manner using MTT assay (Figure S7B). There was no significant difference in the change of mitochondrial membrane potential and cell viability between FTH-BCSCs and BCSCs after treatment with docetaxel. Thus, we conclude that the ferritin overexpression did not affect the BCSCs’ response to docetaxel treatment.

**The Viable Cell Populations within the Tumors Exhibit the BCSC Phenotype and High Levels of Proliferative Markers**

To investigate the effects of docetaxel treatment on FTH-BCSC tumors, double staining for CD44 and CD24 was performed on FTH-BCSC and FTH-BCSC Doc tumors. Because the cells located in the periphery and center of the tumor responded differently to docetaxel, CD44 and CD24 expression was analyzed in both regions (Figure 5A). The periphery of the FTH-BCSC Doc tumors contained significantly higher proportions of CD44+/CD24+ BCSCs compared to the periphery and center of the FTH-BCSC tumors (FTH-BCSC periphery and center: 58.46±2.07% and 44.35±4.82%; FTH-BCSC Doc periphery and center: 71.38±3.75% and 56.13±2.59%, P<0.05) (Figure 5B). CD44+/CD24+ and CD44−/CD24− cells were detected in the periphery and center of FTH-BCSC and FTH-BCSC Doc tumors. However, the proportion of these cells was not significantly different between FTH-BCSC and FTH-BCSC Doc tumors.

We investigated the cell proliferation marker PH3 to determine whether docetaxel alters tumor cell proliferation. The percentage of cells expressing PH3 in the EGFP-positive cell population was analyzed in the periphery and center of FTH-BCSC and FTH-BCSC Doc tumors. Significantly higher percentage of PH3-positive cells were observed in the periphery and center of the FTH-BCSC Doc tumors (FTH-BCSC periphery and center: 97.0±0.04% and 83.0±0.19%, FTH-BCSC Doc periphery and center: 11.48±0.90% and 9.32±1.38%, P<0.01) (Figure 5C and D).

**Discussion**

The results of our study suggest that ferritin-based MRI can be used as a noninvasive method to identify viable cell populations in tumors after chemotherapy. In the present study, BCSCs transduced with FTH and EGFP dual reporter genes were transplanted into NOD/SCID mice to noninvasively track BCSC-derived populations during tumor growth and monitor tumor responses after chemotherapy. MRI showed distinct populations of pixels with high R2* values in the docetaxel-treated FTH-BCSC tumors, which correspond to EGFP+ viable cell populations with a high percentage of CD44+/CD24− cells, as observed by histology. We confirmed that lentiviral transduction of the reporter genes did not alter the characteristics of BCSCs, as was revealed by the cell surface marker analysis, proliferation assays, and in vivo tumor growth. To the best of our knowledge, this study is the first to track and image CSCs isolated from human tumor specimens and to show viable cell populations of tumors after chemotherapy in living mice with MRI reporter genes. We believe that our experimental model system can be used to identify the most effective treatments for tumors derived from BCSCs and to develop new therapeutic strategies to target both BCSCs and non-BCSCs to achieve durable remission [8,9,18,32].

In general, accumulation of iron in the cancer cells may have adverse effects on the host since iron is pivotal nutrient for proliferation and growth in normal cells as well as cancer cells. Some studies reported high iron concentration promoted the cancer cell proliferation by overexpressing transferrin receptor that could elevate the level of reactive soluble iron in cells [33,34].
However, the study reported by Cohen et al. [22] and our study demonstrated iron accumulation by ferritin overexpression did not alter breast cancer cell proliferation and viability in vitro [25]. These results suggest that ferritin overexpression can detoxify the reactive free iron not to affect the proliferation and growth of cancer cell, even the increase in net intracellular iron amount by inducing iron uptake.

A notable finding in this MRI study was the distinctive $R_2^*$ value distribution found in FTH-BCSC tumors after chemotherapy. After 14 days of docetaxel treatment, a population of pixels with high $R_2^*$ values appeared in the FTH-BCSC tumors while the mean $R_2^*$ values of tumors were significantly decreased. In contrast, untreated BCSC, FTH-BCSC and docetaxel-treated BCSC tumors did not show this distinctive $R_2^*$ value distribution. All $R_2^*$ values for the control tumors showed a normal distribution. Pixels that represented a distinct population and measured over the threshold (mean +3 SDs) in the FTH-BCSC Doc tumors occupied approximately 50% of the total pixels, while the percentages for control tumors were under 30%. These findings support the result that cell populations with different $R_2^*$ value distributions were distinguished by FTH overexpression. Finally, tissue analysis confirmed that the viable cells in the FTH-BCSC tumors after chemotherapy were only located in regions with high $R_2^*$ values, while the viable cells in the BCSC tumors were in both regions with low and high $R_2^*$ values. Together, these findings imply that MRI analysis using a ferritin reporter can identify and quantify the existence of cells that survive after chemotherapy even before the tumor changes in size.

To monitor the BCSC tumor response to chemotherapy, our bimodal imaging approach based on FTH-EGFP dual reporter
Figure 4. Histological analysis of the peripheral and central portions of control (BCSC and FTH-BCSC) and docetaxel-treated (BCSC Doc and FTH-BCSC Doc) xenograft tumors. (A–D) MRI images and H&E staining of BCSC, BCSC Doc, FTH-BCSC and FTH-BCSC Doc tumors obtained 4 weeks after the implantation. The red and the black boxes on the MRI images indicate the corresponding areas to H&E staining images of...
the periphery and the center of each tumor. The white dotted lines on the MRI images indicate the boundary where the $R_2^*$ values were differed in the BCSC Doc and FTH-BCSC Doc tumors. The black dotted lines on H&E staining indicate the demarcation between viable and nonviable cells area in the central portions of the BCSC Doc and FTH-BCSC Doc tumors (x100; bar in H&E, 100 μm, bar in MRI, 500 μm). MRI images before magnification and cropping are in the Supplement (Figure S5). (E) Immunostaining of EGFP and myc-FTH in FTH-BCSC and FTH-BCSC Doc tumors. The white dotted line indicates the demarcation between the areas of viable and nonviable cells in the central portion of FTH-BCSC Doc tumors (x400; bar, 50 μm).

doi:10.1371/journal.pone.0052931.g004

Figure 5. Immunohistochemical analysis of the peripheral and central portions of control (FTH-BCSC) and docetaxel-treated (FTH-BCSC Doc) xenograft tumors. (A) Double staining for CD44 and CD24 expression performed in FTH-BCSC and FTH-BCSC Doc tumors (x400; bar, 100 μm). (B) The percentage of CD44+/CD24−, CD44+/CD24+, CD44−/CD24+, CD44−/CD24− and EGFP-positive cells in the periphery and center of the FTH-BCSC and FTH-BCSC Doc tumors. *P<0.05. (C) Cell proliferation marker (phospho-histone 3, PH3) expression in the FTH-BCSC and FTH-BCSC Doc tumors (x200; bar, 100 μm). (D) The percentage of PH3-positive/EGFP-positive cells in the periphery and center of the FTH-BCSC and FTH-BCSC Doc tumors. **P<0.01.

doi:10.1371/journal.pone.0052931.g005
viable cells [25,27,35,36]. Tissue samples from tumors could be obtained without sacrifice of animals by using an MRI-guided biopsy system [37]. Furthermore, quantitative analyses of the MRI data enabled the evaluation of anti-tumor effects in different areas within the tumor, which is difficult with other in vivo methods. In this study, a higher percentage of cells with the CD44+/CD24− phenotype was found in the remaining viable cells in the docetaxel-treated FTH-BCSC tumors than in the untreated FTH-BCSC tumors. This result demonstrates that more cells with the BCSC phenotype are present in docetaxel-treated tumors, which is consistent with results of previous studies [6]. In the future clinical trials, the efficacy of CSC-targeting therapies is likely be monitored in vivo with MRI and SPIO nanoparticle-labeling of anti-CSC markers while our imaging approach with bimodal reporter genes is more suitable for studying dynamic processes or tumor cells to stroma interaction in preclinical animal tumor models [32,38–41].

In conclusion, our results show that ferritin-based MRI, which offers high spatial resolution and tissue contrast, can effectively identify and localize remaining viable cell populations derived from BCSCs after chemotherapy and may represent a novel tool to monitor the efficacy of CSC-targeting therapies in vivo. The experimental model system used in this study could be easily applied to other cancer types, such as prostate, colon, pancreas, liver and brain tumors.

Supporting Information

Figure S1 Biological properties of the human BCSCs and FTH-BCSCs. (A) The abilities to form mammospheres did not differ between BCSCs and FTH-BCSCs. (B) A BCSC marker (CD49f high), mesenchymal lineage markers (CD90 high), and a hematopoietic stem cell marker (CD34−) were analyzed by flow cytometry in BCSCs. (C) CD marker expression levels of FTH-BCSCs were similar to those of BCSCs (CD49f high, CD90 high, and CD34−).

Figure S2 Comparison of tumor-forming abilities and fluorescence imaging of BCSCs and FTH-BCSC-derived tumors. (A) Tumor-forming abilities were similar for BCSCs and FTH-BCSCs, and in vivo live imaging confirmed that only the FTH-BCSC tumors expressed EGFP fluorescence. The red dotted circle indicates the BCSC tumor and the yellow dotted circle indicates the FTH-BCSC tumor. (B) In vivo EGFP fluorescence of image excised tumors derived from BCSCs and FTH-BCSCs. The sizes of the BCSCs and FTH-BCSC tumors were similar.

Figure S3 Cell growth analysis and the 7-AAD assay with iron supplementation. (A) There was no significant difference in the growth rates of the BCSCs and FTH-BCSCs in the presence of an iron supplement. (B) The 7-AAD assay revealed that the viabilities of the BCSCs and FTH-BCSCs in the presence of the iron supplement were not significantly different.

References

1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983–3988.
2. Dean M, Fojo T, Bates S (2005) Tumor stem cells and drug resistance. Nat Rev Cancer 5: 273–284.
3. Phillips TM, McBride WH, Pajenk F (2006) The response of CD24−/low/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 98: 1777–1785.
4. Yu F, Yao H, Zhu P, Zhang X, Pan Q, et al. (2007) let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131: 1109–1123.
5. Liu R, Wang X, Chen GY, Dalerba P, Gurney A, et al. (2007) The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 356: 672–679.
6. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, et al. (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100: 672–679.
7. Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 50 Suppl 1: 122S–150S.
8. Hart LS, El-Deiry WS (2008) Invincible, but not invisible: imaging approaches toward in vivo detection of cancer stem cells. J Clin Oncol 26: 2901–2910.

9. Foster P (2011) Imaging cancer stem cells; AL A, editor: Humana Press. 297–309 p.

10. Guo W, Jeltsch J, Weisleder R (2010) In vivo imaging in cancer. Cold Spring Harb Perspect Biol 2: a003818.

11. Ignatius MS, Chen E, Elpek NM, Fuller AZ, Tenente EM, et al. (2012) In vivo imaging of tumor-propagating cells, regional tumor heterogeneity, and dynamic cell movements in embryonal rhabdomyosarcoma. Cancer Cell 21: 600–609.

12. Snyder EL, Bailey D, Shipitsin M, Polyak K, Loda M (2009) Identification of CD44+/CD24− breast carcinoma cells in primary human tumors by quantum dot-conjugated antibodies. Lab Invest 89: 857–866.

13. Vlahi E, Kim K, Lagadec C, Donna LD, McDonald JT, et al. (2009) In vivo imaging, tracking, and targeting of cancer stem cells. J Natl Cancer Inst 101: 350–359.

14. Liu H, Patel MR, Prescher JA, Patial A, Qian D, et al. (2010) Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc Natl Acad Sci U S A 107: 10115–10120.

15. Yoshi Y, Furukawa T, Kiyono Y, Watanabe R, Waki A, et al. (2010) Copper-64-diacyctyl-bis-(N4-methylthiosemicarbazone) accumulates in rich regions of CD133+ highly tumorigenic cells in mouse colon carcinoma. Nucl Med Biol 37: 395–404.

16. Xia T, Jiang H, Li C, Tian M, Zhang H (2012) Molecular imaging in tracking tumor stem-like cells. J Biomed Biotechnol 2012: 420364.

17. Shigdar S, Lin J, Li Y, Yang CJ, Wei M, et al. (2012) Cancer stem cell targeting: the next generation of cancer therapy and molecular imaging. Ther Deliv 3: 237–244.

18. McLaughlin R, Hython N (2011) MRI in breast cancer therapy monitoring. NMR Biomed 24: 712–720.

19. Cao W, Frank JA (2009) Detection and quantification of magnetically labeled cells by cellular MRI. Eur J Radiol 70: 258–264.

20. Long CM, Bulte JW (2009) In vivo tracking of cellular therapeutics using magnetic nanoclusters for detection of CD44-overexpressing breast cancer by cellular MRI. Eur J Radiol 70: 258–264.

21. Bair S, Spaulding E, Parkkinen J, Shulman HM, Lesnikov V, et al. (2009) Transplantation of allogenic T cells alters iron homeostasis in NOD/SCID mice. Blood 113: 1841–1844.

22. Viwader JE, Lindeman GJ (2012) Cancer stem cells: current status and evolving complexities. Cell Stem Cell 10: 293–309.

23. McLaughlin R, Hython N (2011) MRI in breast cancer therapy monitoring. NMR Biomed 24: 712–720.

24. Kim HS, Cho HR, Choi SH, Woo JS, Moon WK (2010) In vivo imaging of tumor transduced with bimodal lentiviral vector encoding human ferritin and green fluorescent protein on a 1.3 T clinical magnetic resonance scanner. Cancer Res 70: 7313–7324.

25. Naumov AV, Reinecke H, Yarnyk V, Deen J, Yuan C, et al. (2010) Ferritin overexpression for noninvasive magnetic resonance imaging-based tracking of stem cells transplanted into the heart. Mol Imaging 9: 201–210.

26. Townsend JR, Ramadass SS, Smedrea C, Rutt BK, MacDonald RC, et al. (2009) Three-dimensional imaging and quantification of both solitary cells and metastases in whole mouse liver by magnetic resonance imaging. Cancer Res 69: 8326–8331.

27. Choi SH, Cho HR, Kim HS, Kim YH, Kang KW, et al. (2012) Imaging and quantification of metastatic melanoma cells in lymph nodes with a ferritin MR reporter in living mice. NMR Biomed 25: 737–745.

28. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, et al. (2005) Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 65: 5506–5511.

29. Eiree R, Sing J, Raoul A, Tushavbi G, Aparicio S, et al. (2008) A method for quantifying normal human mammary epithelial stem cells with in vivo regenerative ability. Nat Med 14: 1384–1389.

30. Eiree R, Sing J, Raoul A, Tushavbi G, Aparicio S, et al. (2008) A method for quantifying normal human mammary epithelial stem cells with in vivo regenerative ability. Nat Med 14: 1384–1389.

31. Bair S, Spaulding E, Parkkinen J, Shulman HM, Lesnikov V, et al. (2009) Transplantation of allogenic T cells alters iron homeostasis in NOD/SCID mice. Blood 113: 1841–1844.

32. Viwader JE, Lindeman GJ (2012) Cancer stem cells: current status and evolving complexities. Cell Stem Cell 10: 293–309.

33. Medarova Z, Rashkovetsky L, Pantazopoulos P, Moore A (2009) Multi-parametric monitoring of tumor response to chemotherapy by noninvasive imaging. Cancer Res 69: 1182–1189.

34. Penet MF, Mikhaylova M, Li C, Krishnamachary R, Blunde K, et al. (2010) Applications of molecular MRI and optical imaging in cancer. Future Med Chem 2: 975–988.

35. Flegel T, Oevermann A, Ochtering G, Matiasik K (2012) Diagnostic yield and adverse effects of MRI-guided free-hand brain biopsies through a Mini-Burr hole in dogs with encephalitis. J Vet Intern Med.